## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.14 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (58% of avg), overbought RSI (71).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($192.07)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Backbone of Discovery: A Deep Dive into Charles River Laboratories (CRL)**
- Source: FinancialContent | 20251223T101000 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories (CRL) is an indispensable backbone of the global pharmaceutical industry, participating in the development of over 80% of FDA-approved drugs in the last five years. After a tumultuous period, CRL is undergoing a strategic realignment with a $1 billion buyback program and a pivot towards AI-driven discovery, aiming to evolve into a high-tech drug development powerhouse. The company's business model spans Discovery and Safety Assessment, Research Models and Services, and Manufacturing Solutions, with its stock recovering in 2025 due to regulatory resolutions and a focus on shareholder returns.

**2. Why Charles River Laboratories (CRL) Stock Is Trading Up Today**
- Source: Finviz | 20251222T110905 | Bullish | Relevance: 100%
- Shares of Charles River Laboratories (CRL) rose 2.9% after BofA Securities upgraded the stock to Buy with a $225 price target, citing its strong position in early-stage pharmaceutical research. This positive momentum was further fueled by the U.S. Securities and Exchange Commission concluding its investigation into the company without any enforcement action, removing a key investor uncertainty. The stock reached a new 52-week high, finishing up 3.3% from its previous close.

**3. Corient Private Wealth LLC Raises Holdings in Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251224T090820 | Bullish | Relevance: 100%
- Corient Private Wealth LLC significantly increased its stake in Charles River Laboratories International (NYSE:CRL) by 129.3% in Q2, acquiring an additional 6,669 shares. This brings their total holdings to 11,825 shares, valued at approximately $1.79 million. The company recently surpassed quarterly earnings estimates, and analysts maintain a "Moderate Buy" consensus rating with an average target price of $195.93.

**4. Charles River Laboratories (CRL): Valuation Check After SEC Clearance and BofA Upgrade Lift the Stock**
- Source: Simply Wall Street | 20251223T090801 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories (CRL) recently saw its stock climb about 3% after the U.S. SEC closed its investigation without enforcement action and BofA Securities upgraded the company. This relief rally adds to significant recent momentum, though a Simply Wall St narrative suggests the stock is 7.5% overvalued with a fair value of $188.93, while market ratios offer a different perspective.

**5. Charles River Laboratories stock hits 52-week high at $200.96 By Investing.com**
- Source: Investing.com Nigeria | 20251222T150819 | Bullish | Relevance: 100%
- Charles River Laboratories International Inc. (CRL) reached a new 52-week high of $200.96, reflecting a 7.25% positive change over the past year and a 33.65% 6-month price return. Despite current losses, analysts forecast profitability for FY2025, with several firms upgrading their ratings and price targets for the company.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.14 indicates undervaluation relative to growth. Forward P/E 18.6x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 1.64 |
| 52W Range | $91.86 - $204.47 |
| Short Interest | 6.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.14 |
| Forward P/E | 18.6 |
| Current P/E | 19.9 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.5% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 at 0.7% confirms short-term momentum alignment. AM_20 at 6.9% shows strong absolute momentum above own 20MA. Outperforming sector by 5.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.06), confirming momentum. RSI overbought at 71, risk of mean reversion. Volume at 58% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 5.69% (CS: 94) | Strong |
| RSI_14 | 71.1 | Overbought |
| MACD Histogram | 1.06 | Bullish |
| vs SMA20 | 1.069x | Above |
| vs SMA50 | 1.120x | Above |
| vs SMA200 | 1.289x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $203.35
- **Stop Loss:** $192.07 (5.5% risk)
- **Target:** $225.91 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 106
- **Position Value:** $21,555.10
- **Portfolio %:** 21.56%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*